Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Modernization and supply chain diversity drive new growth
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
Donation drive in São Paulo aims to support 250 young women’s health and environmental responsibility
Subscribe To Our Newsletter & Stay Updated
